If you’re a power user of webcams for Zoom or any other video calls, the EliteBook 1040 G11 is challenging to ignore. And even if you don’t care about the camera, it’s just a fantastic ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 (https://www.sanofi.com/en/media-room/press-releases/2025/ ...

In 2024, Sanofi (NASDAQ:SNY) worked hard to become primarily a biopharma company, which included selling a dominant stake in Opella, a major company in the over-the-counter and vitamins ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against the other foreign ...

L’Oreal OR-1.27%decrease; red down pointing triangle will sell part of its stake in Sanofi SAN-0.21%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

In October 2024, Sanofi entered talks with US private equity company Clayton Dubilier & Rice (CD&R) over the sale of Opella, valued at around $17bn. A deal is slated to be completed by Q2 this year.

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

For the Q&A, you have two options in Zoom ... In 2025, Sanofi will receive a cash consideration in the high single-digits in billions in euros from the Opella transaction at the earliest in ...

A €5 billion share buyback program is planned for 2025, aiming to offset Opella dilution and enhance ... potentially impacting market share. Sanofi delivered robust Q4 2024 results with strong ...

Sanofi has plans to separate its Consumer Healthcare [“CHC”] unit through the creation of a publicly listed entity headquartered in Paris called Opella. Sanofi intends to sell a controlling ...

Meanwhile, Sanofi should soon have some extra cash on hand thanks to the expected sale of a controlling stake in its consumer health business Opella to private equity firm Clayton, Dubilier & Rice.